Cosentyx FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved January 21, 2015)
Brand name: Cosentyx
Generic name: secukinumab
Dosage form: Injection
Company: Novartis Pharmaceuticals Corporation
Treatment for: Plaque Psoriasis, Ankylosing Spondylitis, Psoriatic Arthritis
Cosentyx (secukinumab) is a selective interleukin-17A (IL-17A) inhibitor for the treatment of plaque psoriasis, ankylosing spondylitis, psoriatic arthritis, and non-radiographic axial spondyloarthritis.
Development Timeline for Cosentyx
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.